A5050180368- Renal Diseases and Glomerulopathies
- Renal and Vascular Pathologies
- Chronic Kidney Disease and Diabetes
- Vasculitis and related conditions
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Systemic Sclerosis and Related Diseases
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Biomedical Research and Pathophysiology
- Fibroblast Growth Factor Research
- Platelet Disorders and Treatments
- Urticaria and Related Conditions
- Organ Donation and Transplantation
- Pregnancy and Medication Impact
- Ureteral procedures and complications
- Ovarian cancer diagnosis and treatment
- Urological Disorders and Treatments
- Autoimmune Bullous Skin Diseases
Manchester University NHS Foundation Trust
2022-2025
University of Manchester
2023-2025
Manchester Academic Health Science Centre
2023-2025
Wellcome Centre for Cell-Matrix Research
2023
Manchester Royal Infirmary
2021-2023
Southmead Hospital
2022
Manchester Metropolitan University
2021
Derriford Hospital
2020
Abstract Background and hypothesis The PLA2R antibody test is a valuable first-line diagnostic tool for primary membranous nephropathy (MN), helping to identify PLA2R-related MN potentially eliminating the need kidney biopsy in some individuals. By reducing reliance on biopsies, streamlines diagnosis improves patient care. However, determining optimal measurement method cut-off critical maximising benefits of minimising any harms. Methods A systematic review meta-analysis were performed...
Focal segmental glomerulosclerosis (FSGS) is a common cause of nephrotic syndrome and renal failure, requiring transplantation. However, FSGS can often recur after transplantation resulting in graft failure. The most used therapeutic intervention for rFSGS plasma exchange (PE), with variable success. Recently, rituximab has found increasing use both treatment prevention recurrent FSGS. We undertook systematic review ± preventative exchange, or combination Studies published between 2017 2024...
Since the emergence of anti-PLA2R antibody (PLA2R-Ab) test, nephrology practice has not changed dramatically, with most nephrologists still relying on a kidney biopsy to diagnose membranous nephropathy. In this study, we examined clinical accuracy test using ELISA in routine care.We conducted retrospective analysis PLA2R-Ab testing 187 consecutive patients seen at single UK centre between 2003 and 2020. We compared findings PLA2R-ab test. Patients' demography, urine protein creatinine...
The prognostic value of PLA2R antibody (Ab) test in clinical practice remains unclear. We aimed to evaluate its ability predicting hard outcomes primary membranous nephropathy (PMN) after adjustments conventional markers disease activity.A total 222 patients diagnosed with PMN from January 2003 July 2019 having had a serum Ab test, were included 3 centers the north England. Baseline markers, PLA2R-Ab-status (positive vs. negative), Ab-titer (high low), and time testing (pre-PLA2R era era)...
Therapy of primary membranous nephropathy (PMN) with progressive advanced kidney dysfunction is challenging limited literature and no clear therapeutic strategies. This due to the scant evidence effectiveness uncertainty around risk-benefit profile immunosuppression (ImS) when eGFR less than 30 mL/min. We aimed determine long-term clinical outcomes in patients PMN severe renal impairment treated combined cyclophosphamide steroids.The study a single-center retrospective longitudinal cohort...
Thromboembolic events (TEEs) are a serious and potentially fatal complication of nephrotic syndrome (NS). Despite this, there is lack evidence examining the benefits prophylactic anticoagulation (PAC) in NS. It was our objective to review risk factors, rates TEEs, patterns PAC patients with primary NS, aim provide pragmatic approach NS.This retrospective longitudinal cohort study adult Included were as follows: biopsy-proven minimal change disease focal segmental glomerulosclerosis...
Pemetrexed is an anti-folate agent which inhibits enzymes involved in purine and thymidine nucleotide synthesis. It has found use the treament of several cancers, especially pleural mesotheliomas non-small cell lung cancers (NSCLC). It's known to cause adverse effects related myelosuppression (similar other agents). However, it generally considered safe as a treatment these aggressive cancers. Further, nephrotoxicity secondary be rare.
Thromboembolism (TE) is a recognised adverse complication of Nephrotic syndrome (NS). The rates thromboembolism range between 3 and 36% includes both venous arterial events. Despite this, the relative frequency NS, there concerning lack evidence to guide at what point prophylactic anticoagulation should be initiated, with agent when withhold. Only three cohort studies exist examining this question, combined patient population 277. KDIGO states that: Prophylactic full dose 'considered' in...
Abstract Background and Aims International guidelines do not recommend specific use of immunosuppression treatment in membranous nephropathy patients presenting with an estimated glomerular filtration rate <30ml/min/1.73m2. This is due to the scant published evidence effectiveness uncertainty around toxic effects at this stage. In study, we sought examine safety combined cyclophosphamide steroids primary advanced kidney disease. Method a retrospective study 18 biopsy confirmed who...
Ragy, Omar S.; Rautemaa, Vilma; Kanigicherla, Durga Anil K; Hamilton, Patrick Author Information